Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CMML: Clinical and molecular aspects.

Literature DB >> 28455647

CMML: Clinical and molecular aspects.

Raphael Itzykson^1,2, Matthieu Duchmann³, Nolwenn Lucas³, Eric Solary^3,4.

Abstract

Chronic Myelomonocytic Leukemia is a chronic myeloid neoplasm occurring mostly in the elderly with overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) characterized by chronic monocytosis. Recent progresses in the molecular and cellular pathogenesis of CMML have stirred a renewed interest in this clinically heterogeneous disorder. Here, we review the recent progresses in the biology of CMML and how it affects its current and future clinical management.

Entities: Disease

Keywords: Chronic myelomonocytic leukemia; Myelodysplastic; Myeloproliferative

Mesh：

Year: 2017 PMID： 28455647 DOI： 10.1007/s12185-017-2243-z

Source DB: PubMed Journal: Int J Hematol ISSN： 0925-5710 Impact factor: 2.490

69 in total

1. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?

Authors: Hans Carl Hasselbalch
Journal: Blood Date: 2012-02-07 Impact factor: 22.113

2. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.

Authors: Francesco Onida; Hagop M Kantarjian; Terry L Smith; Greg Ball; Michael J Keating; Elihu H Estey; Armand B Glassman; Maher Albitar; Monica I Kwari; Miloslav Beran
Journal: Blood Date: 2002-02-01 Impact factor: 22.113

3. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice.

Authors: José J Fuster; Susan MacLauchlan; María A Zuriaga; Maya N Polackal; Allison C Ostriker; Raja Chakraborty; Chia-Ling Wu; Soichi Sano; Sujatha Muralidharan; Cristina Rius; Jacqueline Vuong; Sophia Jacob; Varsha Muralidhar; Avril A B Robertson; Matthew A Cooper; Vicente Andrés; Karen K Hirschi; Kathleen A Martin; Kenneth Walsh
Journal: Science Date: 2017-01-19 Impact factor: 47.728

4. The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands.

Authors: Avinash G Dinmohamed; Yvette van Norden; Otto Visser; Eduardus F M Posthuma; Peter C Huijgens; Pieter Sonneveld; Arjan A van de Loosdrecht; Mojca Jongen-Lavrencic
Journal: Leuk Res Date: 2014-12-04 Impact factor: 3.156

5. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.

Authors: Ana Alfonso; Guillermo Montalban-Bravo; Koichi Takahashi; Elias J Jabbour; Tapan Kadia; Farhad Ravandi; Jorge Cortes; Zeev Estrov; Gautam Borthakur; Naveen Pemmaraju; Marina Konopleva; Carlos Bueso-Ramos; Sherry Pierce; Hagop Kantarjian; Guillermo Garcia-Manero
Journal: Am J Hematol Date: 2017-05-26 Impact factor: 10.047

6. TET proteins regulate the lineage specification and TCR-mediated expansion of iNKT cells.

Authors: Ageliki Tsagaratou; Edahí González-Avalos; Sini Rautio; James P Scott-Browne; Susan Togher; William A Pastor; Ellen V Rothenberg; Lukas Chavez; Harri Lähdesmäki; Anjana Rao
Journal: Nat Immunol Date: 2016-11-21 Impact factor: 25.606

7. Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia.

Authors: Alyssa Carey; David K Edwards; Christopher A Eide; Laura Newell; Elie Traer; Bruno C Medeiros; Daniel A Pollyea; Michael W Deininger; Robert H Collins; Jeffrey W Tyner; Brian J Druker; Grover C Bagby; Shannon K McWeeney; Anupriya Agarwal
Journal: Cell Rep Date: 2017-03-28 Impact factor: 9.423

8. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.

Authors: Sa A Wang; Lloyd Hutchinson; Guilin Tang; Su S Chen; Patricia M Miron; Yang O Huh; Dan M Jones; Carlos Bueso-Ramos; Srdan Verstovsek; L Jeffrey Medeiros; Roberto N Miranda
Journal: Am J Hematol Date: 2013-03 Impact factor: 10.047

9. Risk assessment in chronic myelomonocytic leukemia (CMML).

Authors: U Germing; A Kündgen; N Gattermann
Journal: Leuk Lymphoma Date: 2004-07

10. Control of Foxp3 stability through modulation of TET activity.

Authors: Xiaojing Yue; Sara Trifari; Tarmo Äijö; Ageliki Tsagaratou; William A Pastor; Jorge A Zepeda-Martínez; Chan-Wang J Lio; Xiang Li; Yun Huang; Pandurangan Vijayanand; Harri Lähdesmäki; Anjana Rao
Journal: J Exp Med Date: 2016-02-22 Impact factor: 14.307

16 in total

1. Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics.

Authors: Abhishek A Mangaonkar; Mrinal M Patnaik
Journal: Adv Cell Gene Ther Date: 2019-01-16

2. Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance.

Authors: Wenmin Han; Feng Zhou; Zheng Wang; Haiying Hua; Wei Qin; Zhuxia Jia; Xiaohui Cai; Meiyu Chen; Jie Liu; Hongying Chao; Xuzhang Lu
Journal: Int J Hematol Date: 2021-08-27 Impact factor: 2.490

3. Prognostic implication of early minimal residual disease evaluation in patients with chronic myelomonocytic leukemia.

Authors: Lulu Wang; Rongrong Chen; Li Li; Lixia Zhu; Xianbo Huang; Xiujin Ye
Journal: Am J Cancer Res Date: 2022-05-15 Impact factor: 5.942

4. CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia.

Authors: Junichi Watanabe; Ken Sato; Yukiko Osawa; Toshikatsu Horiuchi; Shoichiro Kato; Reina Hikota-Saga; Takaaki Maekawa; Takeshi Yamamura; Ayako Kobayashi; Shinichi Kobayashi; Fumihiko Kimura
Journal: Int J Hematol Date: 2018-03-29 Impact factor: 2.490